HUDSON INNOVATIONS

Dr. Forrest possesses extensive experience and field knowledge of the pharmaceutical development environment in Asia, especially Japan, where he served as Board Member, Corporate Officer and Head of R&D for Wyeth K.K. He oversaw the local product approvals for etanercept and gemtuzumab ozogamicin, as well as product registration submissions for a pneumococcal conjugate vaccine, bazedoxifene, temsirolimus, venlafaxine and tigecycline; and, was responsible for developing a successful strategy for the integration and coordination of development activities across the major markets in East Asia.

Also known as: Hudson Innovations, LLC